{"id":"W4220672244","doi":"10.1158/1078-0432.ccr-21-3087","title":"A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research","funders":"National Cancer Institute; Ipsen; Shionogi; Astellas Pharma; Eisai; National Institute for Health and Care Research; Cancer Research UK; Genentech; MEI Pharma; Incyte; Taiho Pharmaceutical; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tolerability; Medicine; Adverse effect; Abiraterone acetate; Prostate cancer; Pharmacodynamics; Rash; Pharmacokinetics; Internal medicine; Pharmacology; Cancer; Oncology; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008335905,0.001048832,0.001312143,0.0002801501,0.0003231181,0.0005320398,0.000460782,0.0006040222,0.002125859],"category_scores_gemma":[0.0004456564,0.0003626189,0.0006925087,0.0003731183,0.0005665424,0.0004977586,0.0002415248,0.00177567,0.000571767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005000541,"about_ca_system_score_gemma":0.001139717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003688427,"about_ca_topic_score_gemma":0.001112762,"domain_scores_codex":[0.9997274,0.0001136323,0.00002129314,0.00005417527,0.00003800077,0.00004540279],"domain_scores_gemma":[0.999648,0.00005423299,0.00009214615,0.00003202247,0.00002665792,0.0001469845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4740212,0.07483208,0.02082303,0.002060988,0.001622189,0.0006542015,0.0004250745,0.005756188,0.2063701,0.0004259181,0.003923324,0.2090857],"study_design_scores_gemma":[0.3024374,0.6558548,0.02062203,0.0000390486,0.0005399908,0.0007343158,0.00005573528,0.001314266,0.01373947,0.000151986,0.004483768,0.00002727306],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944267,0.002042971,0.0005363307,0.0001660334,0.0000414055,0.001137788,0.0004885459,0.00004367774,0.001116534],"genre_scores_gemma":[0.992301,0.001907352,0.001548229,0.0003774168,0.00009810357,0.0009904917,0.001400647,0.00001187753,0.001364973],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002125859,"threshold_uncertainty_score":0.007111728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07900168100914737,"score_gpt":0.477995984189011,"score_spread":0.3989943031798636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}